Cervical cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, United States· US$762,815 awarded in fiscal year 2026· until Jun 2031

• NIH NCI · R01

  Enhancing Cervical Cancer Screening through Integrated Care in Rural North Carolina

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$607,403 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Comparative Modeling to Inform Cervical Cancer Prevention Policies and Practice in the United States

  Tulane University of Louisiana· New Orleans, United States· US$1,084,939 awarded in fiscal year 2026· until Aug 2031

• NIH NIDCR · R56

  Screening for HPV-related oropharyngeal cancer

  Johns Hopkins University· Baltimore, United States· US$979,697 awarded in fiscal year 2026· until Sept 2028

• NIH NCCIH · R34

  Feasibility Study to Increase use of non-Pharmacological Therapies for Chronic Low Back Pain

  Rand Corporation· Santa Monica, United States· US$757,923 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,493,450· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €6,602,445· until Dec 2029· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spain· EU contribution €3,613,288· until May 2028· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €1,996,250· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norway· EU contribution €7,984,441· until Aug 2027· 6 countries

10 of 326 running projects, newest first. Listed amounts together: US$202.2m + €23.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Source

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· AstraZeneca· Source

• A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan

  NCT06925113· Daiichi Sankyo· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 65
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 15

• Circulating inflammatory proteins mediate the causal relationship between blood alliin and cancer: A two-step, multivariable Mendelian randomization study.

  Medicine (Baltimore), Nov 2026

• Epidemiological characteristics of cervical cancer in Asian populations and risk factor inference based on Mendelian randomization.

  Medicine (Baltimore), Oct 2026

• Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs.

  Medicine (Baltimore), Sept 2026

• Polygenic risk scores and plasma proteomics identify cancer-related proteins and trans-regulated protein networks.

  Cell Genom, Aug 2026

• Causal effects of blood and urinary biomarkers on cancer risk: A Mendelian randomization study.

  J Int Med Res, Jul 2026

• Bidirectional mendelian randomization identifies plasma proteins associated with cervical cancer risk.

  J Egypt Natl Canc Inst, Jul 2026

• Absence of causal association between CD40-CD40L signaling and cervical cancer risk: A Mendelian randomization study.

  Medicine (Baltimore), May 2026

• Genome-Wide DNA Methylation Profiling Reveals Ancestry-Associated Epigenetic Reprogramming in Cervical Intraepithelial Neoplasia.

  Int J Mol Sci, Apr 2026

• Heavy metal exposure and cancer risk: Findings from a Mendelian randomization study.

  Toxicol Lett, Feb 2026

• HPV-Driven Cervical Carcinogenesis: Genetic and Epigenetic Mechanisms and Diagnostic Approaches.

  Int J Mol Sci, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.